110822-05-4 Usage
Description
(2-Bromomethyl)-4-methyl-1-nitrobenzene is an aromatic nitro compound and a bromoalkane with a molecular formula of C8H8BrNO2. It features a benzene ring with a nitro group (-NO2) and a bromomethyl group (-CH2Br), along with a methyl group. The presence of the bromine atom and the nitro functional group endows this organic compound with potential reactivity, although specific properties like boiling point, melting point, or solubility may vary based on conditions. Its specialized nature suggests that it is not commonly found or used, and may be reserved for specific scientific or industrial applications.
Uses
Used in Chemical Synthesis:
(2-Bromomethyl)-4-methyl-1-nitrobenzene is used as a chemical intermediate for the synthesis of various organic compounds. Its reactivity, stemming from the nitro and bromine functionalities, makes it a valuable building block in the creation of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Research and Development:
In the scientific community, (2-Bromomethyl)-4-methyl-1-nitrobenzene serves as a research compound for studying the effects of nitro and bromo substituents on the chemical and physical properties of aromatic compounds. It can be utilized to explore reaction mechanisms, investigate the influence of functional groups on molecular behavior, and develop new synthetic methodologies.
Used in Specialty Chemicals Production:
(2-Bromomethyl)-4-methyl-1-nitrobenzene is employed as a key component in the production of specialty chemicals that require unique properties conferred by the nitro and bromo groups. Its application in this industry can lead to the development of new materials with specific characteristics, such as enhanced stability, reactivity, or selectivity in various chemical processes.
Check Digit Verification of cas no
The CAS Registry Mumber 110822-05-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,1,0,8,2 and 2 respectively; the second part has 2 digits, 0 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 110822-05:
(8*1)+(7*1)+(6*0)+(5*8)+(4*2)+(3*2)+(2*0)+(1*5)=74
74 % 10 = 4
So 110822-05-4 is a valid CAS Registry Number.
InChI:InChI=1/C8H8BrNO2/c1-6-2-3-8(10(11)12)7(4-6)5-9/h2-4H,5H2,1H3
110822-05-4Relevant articles and documents
Synthesis of Aryl-Substituted 3,3a,4,5-Tetrahydropyrrolo[1,2- A [ quinolin-1(2 H)-ones and 2,3,4,4a,5,6-Hexahydro-1 H-pyrido[1,2- A [quinolin-1-ones
Watts, Field M.,Bunce, Richard A.
, p. 564 - 572 (2019)
A new route to the title benzo-fused angular tricyclic amides 3,3a,4,5-tetrahydropyrrolo- A nd 2,3,4,4a,5,6-hexahydro-1 H-pyrido[1,2- A [quinolin-1-ones is reported from 1-(tert-butyl) 6-ethyl 3-oxohexanedioate and 1-(tert-butyl) 7-ethyl 3-oxoheptanedioate. Alkylation of these β-keto diesters with a series of 2-nitrobenzyl bromides followed by acid hydrolysis and decarboxylation gives ethyl 6-(2-nitrophenyl)-4-oxohexanoates and ethyl 7-(2-nitrophenyl)-5-oxoheptanoates, respectively. Reductive amination under hydrogenation conditions followed by ester hydrolysis and condensative ring closure affords the final lactam products. The reactions proceed cleanly and only two chromatographic purifications are required.
PIPERAZINE SUBSTITUTED AZAPINE DERIVATIVES AND USES THEREOF
-
Paragraph 1165-1166, (2021/04/23)
The present disclosure relates to compounds of Formula (I) and (II): and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for modulating H1 and 5-HT2A receptors and are to be used in the treatment of sleep disorders, such as sleep fragmentation, disturbed sleep/arousals, and arousal threshold.
JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE
-
Page/Page column 75; 76, (2014/10/04)
Compounds having activity as inhibitors of ALK2 kinase and/or JAK2 kinase are disclosed. The compounds have the following structure (I): [FORMULA SHOULD BE INSERTED HERE] including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, X, z and A are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
